Alflutinib methanesulfonate

SKU: orb1225670

Description

Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical(In Vitro):Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.

Key Properties

• CAS Number: 2130958-55-1
• MW: 664.705
• Purity: >98% (HPLC)
• Formula: C₂₉H₃₅F₃N₈O₅S
• SMILES: CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C.CS(=O)(=O)O
• Target: EGFR
• Solubility: DMSO : 5 mg/mL 7.52 mM

Bioactivity

• In Vitro:
  Firmonertinib mesylate can inhibit EGFR active mutations as well as the T790M acquired resistant mutation.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AST2818 | AST-2818 | ASK120067

Quick Database Links

Gene Symbol

EGFR